CytomX to receive $5M from Regeneron for cancer drug milestone

chanakon laorob
CytomX Therapeutics (CTMX) announced it will receive a $5 million payment after reaching a preclinical milestone in its cancer drug development partnership with Regeneron (REGN). CytomX shares rose 4.6% in extended trading Wednesday.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.